tiprankstipranks
Rain Therapeutics trading resumes
PremiumThe FlyRain Therapeutics trading resumes
4M ago
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
PremiumPress Releases
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
4M ago
Rain Oncology to be Acquired by Pathos AI for $1.16 in cash per share
PremiumThe Fly
Rain Oncology to be Acquired by Pathos AI for $1.16 in cash per share
4M ago
Rain Oncology confirms receipt of unsolicited proposal from Concentra
PremiumThe FlyRain Oncology confirms receipt of unsolicited proposal from Concentra
6M ago
Rain Oncology price target lowered to $1 from $1.50 at Citi
PremiumThe Fly
Rain Oncology price target lowered to $1 from $1.50 at Citi
7M ago
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100